Aroa Biosurgery (ARX) Resumen de Acciones
Aroa Biosurgery Limited desarrolla, fabrica y vende dispositivos médicos para la reparación de heridas y tejidos blandos mediante tecnología de matriz extracelular (MEC) en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
ARX Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Aroa Biosurgery Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | AU$0.56 |
| Máximo en las últimas 52 semanas | AU$0.80 |
| Mínimo de 52 semanas | AU$0.49 |
| Beta | 0.84 |
| Cambio en 1 mes | -7.50% |
| Variación en 3 meses | -11.90% |
| Cambio de 1 año | -19.57% |
| Variación en 3 años | -32.32% |
| Variación en 5 años | -47.89% |
| Variación desde la OPV | -58.89% |
Noticias y actualizaciones recientes
Recent updates
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rentabilidad de los accionistas
| ARX | AU Biotechs | Mercado AU | |
|---|---|---|---|
| 7D | -0.9% | -4.5% | -2.9% |
| 1Y | -19.6% | -16.6% | -2.7% |
Rentabilidad vs. Industria: Los resultados de ARX fueron inferiores a los de la industria Australian Biotechs, que obtuvo un rendimiento del -16.6% el año pasado.
Rentabilidad vs. Mercado: ARX obtuvo unos resultados inferiores a los del mercado Australian, que fueron del -2.7% el año pasado.
Volatilidad de los precios
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.9% |
Precio estable de las acciones: ARX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Australian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ARX (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
Aroa Biosurgery Limited desarrolla, fabrica y comercializa productos sanitarios para la reparación de heridas y tejidos blandos mediante tecnología de matriz extracelular (MEC) tanto en Estados Unidos como a nivel internacional. Entre sus productos se incluyen Endoform Natural y Endoform Antimicrobial Restorative Bioscaffold, destinados al tratamiento de heridas agudas y crónicas; Myriad Matrix, una MEC modificada genéticamente para la reparación y el refuerzo de tejidos blandos, así como para heridas complejas; y los productos Myriad Morcells, Myriad Morcells Fine, Myriad Meshed y Symphony para el tratamiento de heridas de espesor parcial y total, úlceras por presión, úlceras venosas, úlceras diabéticas, úlceras vasculares crónicas, heridas con tunelización o socavación, heridas quirúrgicas, heridas traumáticas y heridas con secreción. La empresa también desarrolla productos para la reconstrucción de la pared abdominal, la reparación de hernias y la reconstrucción mamaria en Norteamérica y Europa.
Resumen de fundamentos de Aroa Biosurgery Limited
| Estadísticas fundamentales de ARX | |
|---|---|
| Capitalización bursátil | AU$190.25m |
| Beneficios(TTM) | AU$3.78m |
| Ingresos (TTM) | AU$84.01m |
¿Está ARX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ARX | |
|---|---|
| Ingresos | NZ$103.85m |
| Coste de los ingresos | NZ$15.03m |
| Beneficio bruto | NZ$88.83m |
| Otros gastos | NZ$84.15m |
| Beneficios | NZ$4.68m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.014 |
| Margen bruto | 85.53% |
| Margen de beneficio neto | 4.50% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ARX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 12:38 |
| Precio de las acciones al final del día | 2026/09/14 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Aroa Biosurgery Limited está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |